文献速递白血病

维奈克拉联合吉瑞替尼治疗FLT3突变复发/难治性急性髓系白血病

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2022-07-18

这项Ib期开放标签、剂量递增/扩展研究纳入61例复发/难治性急性髓系白血病患者(56例FLT3突变),接受维奈克拉400 mg每日一次联合吉瑞替尼80或120 mg每日一次。推荐II期剂量为维奈克拉400 mg联合吉瑞替尼120 mg每日一次,FLT3突变患者改良复合完全缓解率为75%,中位总生存10.0个月。

要点

  • 推荐II期剂量为维奈克拉400 mg每日一次联合吉瑞替尼120 mg每日一次。
  • FLT3突变患者改良复合完全缓解率为75%,中位总生存10.0个月。
  • 无论既往是否接受FLT3抑制剂,改良复合完全缓解率相似(80% vs 67%)。

核心结论

  • 维奈克拉联合吉瑞替尼在FLT3突变复发/难治性急性髓系白血病中与较高的改良复合完全缓解率和FLT3分子学缓解率相关,且与既往是否暴露于FLT3抑制剂无关。
  • 为减轻骨髓抑制需要中断剂量。

研究设计与样本

  • Ib期开放标签、剂量递增/剂量扩展研究(ClinicalTrials.gov标识符:NCT03625505)。
  • 纳入FLT3野生型和FLT3突变(递增阶段)或FLT3突变(扩展阶段)的复发/难治性急性髓系白血病患者。
  • 患者接受维奈克拉400 mg口服每日一次联合吉瑞替尼80 mg或120 mg口服每日一次。
  • 主要目标为安全性、确定推荐II期剂量以及采用ADMIRAL III期定义的反应标准评估的改良复合完全缓解率(完全缓解+血液学计数未完全恢复的完全缓解+血小板计数未完全恢复的完全缓解+形态学无白血病状态)。
  • 共纳入61例患者,其中56例为FLT3突变。

主要发现

  • FLT3突变患者中64%(56例中36例)既往接受过FLT3抑制剂治疗。
  • 推荐II期剂量为维奈克拉400 mg每日一次联合吉瑞替尼120 mg每日一次。
  • 最常见的3/4级不良事件为血细胞减少(49例;80%)。
  • 不良事件导致维奈克拉和吉瑞替尼剂量中断的比例分别为51%和48%。
  • FLT3突变患者的改良复合完全缓解率为75%(完全缓解18%;血液学计数未完全恢复的完全缓解4%;血小板计数未完全恢复的完全缓解18%;形态学无白血病状态36%),既往接受与未接受FLT3抑制剂治疗的患者相似(分别为80% vs 67%)。

关键数值与推荐

  • 中位随访时间为17.5个月。
  • 中位起效时间为0.9个月,中位缓解持续时间为4.9个月(95% CI,3.4至6.6)。
  • 可评估改良复合完全缓解患者中60%(25例中15例)达到FLT3分子学缓解(< 10^-2)。
  • FLT3突变患者的中位总生存为10.0个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML. METHODS: This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III-defined response criteria. RESULTS: Sixty-one patients were enrolled (n = 56 FLT3mut); 64% (n = 36 of 56) of FLT3mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n = 49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (< 10-2) was achieved in 60% of evaluable mCRc patients (n = 15 of 25). The median overall survival for FLT3mut patients was 10.0 months. CONCLUSION: The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure. Dose interruptions were needed to mitigate myelosuppression.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Daver N, Perl AE, Maly J, et al. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022. PMID: 35849791. doi:10.1200/JCO.22.00602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。